Slide background

VAXIL

Creating the ideal immunotherapy

Inducing a Broad
Response

Learn More

universally
Applicable

Learn More

Overcoming
Cancer Resistance

Learn More

Harnessing Potent
Immune Response

Learn More

Tumor
Specific

Learn More

Expression on
Cancer Stem Cells

Learn More

neo-antigen
acting

Learn More

First-ever SP-Specific
Antibody Platform

Learn More

Vaxil’s Lead Products and Orphan Drug Status

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™ platform is ​its Immucin™; ​lead immunotherapy product.

logo-inmucin-slider

Vaxil was founded by Weizmann Institute scientists, Israel’s top research university, in order to provide an altogether novel approach to immunotherapy. Vaxil has diligently advanced its immunotherapy platform and published its research and clinical results in top medical journals.

HIGHTLIGHTS

About Vaxil Immunotherapy


Learn More

About Vaxil’s History


Learn More

Scientific Publications


Learn More

Intellectual Property


Learn More

Immunotherapy has become the most promising field in the fight against cancer. Whereas chemotherapy was once seen as a breakthrough and still utilized successfully in many patients, today’s scientists recognize immunotherapy is the way of the future. Learn More

VAXIL’S PRIMARY PLATFORM GENERATES COMPREHENSIVE IDENTIFICATION, ISOLATION & PRODUCTION OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES Vaxil’s VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. The VaxHit™ platform is essentially a launchpad for novel and uniquely targeted immunotherapy products. Learn More


Vaxil’s team includes executives and scientists with deep industry experience in Israel, the US, and Canada. Supporting Vaxil’s immunotherapy platform development are six specialized PhD scientists.

VAXIL
SCIENTISTS


Learn More

BOARD & EXECUTIVES


Learn More

INVESTOR
PRESENTATIONS


Learn More

VAXIL
LEGAL


Learn More

Vaxil
Announcements


Learn More

in The
News


Learn More

Vaxil
Video


Learn More